Literature DB >> 27080695

Therapy: The NICE position on indications for biologics and biosimilars.

Morton Scheinberg1, Juan J Gomez-Reino2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27080695     DOI： 10.1038/nrrheum.2016.56

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  8 in total

1.  Incentives for market penetration of biosimilars in Belgium and in five European countries.

Authors:  N Swartenbroekx; J Espín; S Gerkens
Journal:  J Pharm Belg       Date:  2014-12

Review 2.  2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Authors:  Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

Review 3.  Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.

Authors:  Matt Stevenson; Rachel Archer; Jon Tosh; Emma Simpson; Emma Everson-Hock; John Stevens; Monica Hernandez-Alava; Suzy Paisley; Kath Dickinson; David Scott; Adam Young; Allan Wailoo
Journal:  Health Technol Assess       Date:  2016-04       Impact factor: 4.014

4.  Inequities in access to biologic and synthetic DMARDs across 46 European countries.

Authors:  Polina Putrik; Sofia Ramiro; Tore K Kvien; Tuulikki Sokka; Milena Pavlova; Till Uhlig; Annelies Boonen
Journal:  Ann Rheum Dis       Date:  2013-03-06       Impact factor: 19.103

5.  Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK.

Authors:  Alex Diamantopoulos; A Finckh; T Huizinga; D K Sungher; L Sawyer; D Neto; F Dejonckheere
Journal:  Pharmacoeconomics       Date:  2014-08       Impact factor: 4.981

6.  Biosimilars: what do patients need to consider?

Authors:  Diana Skingle
Journal:  RMD Open       Date:  2015-09-16

Review 7.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Authors:  Josef S Smolen; Ferdinand C Breedveld; Gerd R Burmester; Vivian Bykerk; Maxime Dougados; Paul Emery; Tore K Kvien; M Victoria Navarro-Compán; Susan Oliver; Monika Schoels; Marieke Scholte-Voshaar; Tanja Stamm; Michaela Stoffer; Tsutomu Takeuchi; Daniel Aletaha; Jose Louis Andreu; Martin Aringer; Martin Bergman; Neil Betteridge; Hans Bijlsma; Harald Burkhardt; Mario Cardiel; Bernard Combe; Patrick Durez; Joao Eurico Fonseca; Alan Gibofsky; Juan J Gomez-Reino; Winfried Graninger; Pekka Hannonen; Boulos Haraoui; Marios Kouloumas; Robert Landewe; Emilio Martin-Mola; Peter Nash; Mikkel Ostergaard; Andrew Östör; Pam Richards; Tuulikki Sokka-Isler; Carter Thorne; Athanasios G Tzioufas; Ronald van Vollenhoven; Martinus de Wit; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2015-05-12       Impact factor: 19.103

8.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maya Buch; Gerd Burmester; Maxime Dougados; Paul Emery; Cécile Gaujoux-Viala; Laure Gossec; Jackie Nam; Sofia Ramiro; Kevin Winthrop; Maarten de Wit; Daniel Aletaha; Neil Betteridge; Johannes W J Bijlsma; Maarten Boers; Frank Buttgereit; Bernard Combe; Maurizio Cutolo; Nemanja Damjanov; Johanna M W Hazes; Marios Kouloumas; Tore K Kvien; Xavier Mariette; Karel Pavelka; Piet L C M van Riel; Andrea Rubbert-Roth; Marieke Scholte-Voshaar; David L Scott; Tuulikki Sokka-Isler; John B Wong; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-10-25       Impact factor: 19.103
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.